03 Feb 2022 Awareness raising

New analysis reveals the stark disparities in cancer rates between ethnic groups

Cancer Research UK has published a new analysis of cancer rates by ethnicity in England, providing crucial data on how some cancer rates vary by ethnicity.

The results were published in the British Journal of Cancer and reveal stark disparities in cancer rates between different ethnic groups.

The study demonstrates the importance of understanding the differences and inequalities in cancer and to highlight where improvements in survival, treatment and care can be made.

Given the renewed focus on the health of minority ethnic groups in the UK during the COVID-19 pandemic, where these groups were disproportionately affected, it is important to now focus on how improvements can be made in relation to cancer diagnosis and treatment. It presents an opportunity for improvements in both policy and practice.

Fiona Hazell, Chief Executive of Leukaemia UK, said:

“We welcome this study and the insights it provides. Addressing health inequalities in cancer prevention, early diagnosis and treatment must be a priority for the UK Government. The 10-year cancer plan provides one opportunity to achieve this but leukaemia and other blood cancers must be included if we’re to improve and save the lives of those affected.

We also encourage the government to support the NHS in ensuring that more ethnicity data is collected so trends like this can be spotted, and interventions made, as soon as possible.”

The study shows that Black people are almost three times more likely to get myeloma. It also shows that Asian people are amongst the most likely to get leukaemia.

Both leukaemia and myeloma are types of blood cancer. Blood cancer is the 5th most common type of cancer and the 3rd biggest cause of cancer deaths in the UK. Further research is vital to improve survival rates as well as the quality of life for those who receive this devastating diagnosis.

With all cancers and across all ethnic groups, awareness of the signs and symptoms is vital to drive improvements in diagnosis, effective treatment and survival.

Fiona Hazell, Chief Executive of Leukaemia UK, added:

“Early diagnosis is key to effective treatment and improving survival from blood cancers. Symptoms such as headaches, fatigue, unusual bruising or bleeding, should not be ignored – and a blood test is vital to achieving an early diagnosis. Don’t hesitate to talk to your GP if you are concerned that you may be experiencing these symptoms.”

Related posts

Sharing this exciting news: a treatment advance for childhood leukaemia

9 May 2018

Sharing this exciting news: a treatment advance for childhood leukaemia

A deal has been struck to let the NHS offer children an expensive new cancer therapy that has been called the most exciting treatment advance for decades

Friends and family of Leicestershire woman who died from rare cancer campaign for more research and awareness

2 August 2023

Friends and family of Leicestershire woman who died from rare cancer campaign for more research and awareness

The family of a Leicestershire woman who died in July 2022, on the day of her leukaemia diagnosis, has raised over £17,000 in her memory to support Leukaemia UK. On…

Less than 1% of Brits can identify all the most common symptoms of one of the deadliest types of cancer

4 September 2023

Less than 1% of Brits can identify all the most common symptoms of one of the deadliest types of cancer

New research launched today by Leukaemia Care and Leukaemia UK reveals that less than 1% (0.4%) of UK adults can accurately identify the four most common symptoms of leukaemia –…

John Goldman Fellowship awarded to Dr Pramila Krishnamurthy

29 November 2021

John Goldman Fellowship awarded to Dr Pramila Krishnamurthy

Leukaemia UK is proud to announce Dr Pramila Krishnamurthy of King’s College Hospital and King’s College London as a Leukaemia UK John Goldman Fellow co-funded by Rosetrees Trust. Dr Krishnamurthy will be using the fellowship to better understand why some leukaemia patients relapse following a stem cell transplant, and how donor lymphocyte infusion can help prevent this.